中華民國藥師公會全國聯合會於2010年起承接中央健康保險局的試辦方案，針對一年就醫100次以上的高就診民眾由培訓及格的藥師執行藥事居家照護，提升病人用藥認知以導正高就診的就醫行為，並解決藥物治療問題，降低用藥風險，提高病人生活品質。
本研究主要目的是呈現提供藥事居家照護四年期間，針對減少門診次數、解決藥物治療問題、提升病人生活品質及減少醫療花費的成效。研究成果以三方向呈現：臨床成果、人性成果及經濟上成果。
自2010年3月至2013年12月的三年十個月，共照護51位高診次病患，經個案簽署同意書後納入研究。依據藥師公會全聯會制定的藥事照護流程，採用病情與用藥評估、擬定與執行照顧計畫、並持續追蹤療效的方式照顧個案，同時記錄發現到的藥物治療問題，針對問題建議解決辦法，並依據測量之結果進行統計分析與比較。
依據研究者成功訪視51位個案之資料分析，平均每人服務7.02次，女性(62.4%)稍多於男性。年齡範圍從36歲到88歲不等，而年齡分布在65~88歲之間的個案人數最多，有35位(68.6%)。以在早期個案平均就診次數，去比較晚期個案平均就診次數，採用t檢定，就診次數有顯著下降(4.98±4.74次比3.13±3.10次，p＜0.05)。
本計畫在人性上之成果是測量個案滿意度與健康相關生活品質。超過90%的個案都很同意且很滿意藥師的服務與價值，並有高的意願繼續接受藥師的照顧。在健康相關生活品質方面，過半數個案的健康相關生活品質有提升，表現最好的可以由30分提升到80分。
從「門診醫療費用」數據分析51位高診次個案，已明顯看出藥師在居家照護輔導個案平均7.02個月以後，99年平均下降29.01%(目標值-10%)，100年平均下降29.48%(目標值-10%)，101年平均下降26.04%(目標值-12%)，102年平均下降26.52%(目標值-12%)。在節省門診醫療總花費方面的成本利益比為1.00:3.56。這代表研究者四年可協助健保局節省門診醫療花費，高達新台幣 938,915元。
四年的成績，已看到藥事居家照護有顯著之成果，可降低高就診民眾的就診次數和減少總門診醫療花費。在目前健保署的「高診次藥事照護試辦計畫」推展實施之下，藥師到高診次病患家中執行藥事照護是可行的且符合成本效益的推廣模式。專業藥師到病人家中與病人訪談中，可以發現病人多重看診用藥，以及其他許多藥物治療問題，經藥師溝通與解決問題，可保障民眾的用藥安全，並減少健保的醫療支出。

The Taiwan Pharmacists Association implemented a pilot project supported by the National Health Insurance Administration and started in 2010. The project was to, with respect to the patients receiving medical treatment for more than 100 times a year, study the outcomes of home pharmaceutical care provided by pharmacists.
This thesis was to present the author’s performance on decreasing the number of clinical visits, identify and resolve drug therapy problems, enhancing quality of life of the patients, and the overall reduction of healthcare expenditures. Therefore, the outcomes of the study were measured from three dimensions: clinical outcomes, humanistic outcomes, and economic outcomes.
This thesis was undertaken from March 2010 to December 2013, a total of three years and 10 months. Total of 51 high users of medical resources were included with their consent to participate the study. Based on the processes of home pharmaceutical care formulated by the Taiwan Pharmacists Association, all information related to patient diseases and drug usage were assessed, care plans were formulated and implemented, then all the actions and resolutions were followed up and recorded.
Of the total 51 patients under the study period, pharmacist conducted in average 7.02 home visits per patient. Their age ranges from 36 to 88 years old and the female patients accounts for 62.4%. Patients in the range of 65 to 88 years old have the largest number, 35 persons, and accounts for 68.6% of the total. Number of clinical visits at early and late stages showed significant decreased from 4.98±4.74 to 3.13±3.10.
More than 90 % of the patients under this study were highly agreed that pharmacist can indeed help them, and highly satisfied with the home care service offered by the pharmacists, and patients are willing to continue such pharmaceutical care performed by the pharmacists. In addition, more then half of the patients their health related quality of life increased with some increased even from 30 up to 80, on a scale of 0 ~ 100.
The economic outcome using reduction of outpatient healthcare expenditure as indicator also showed that after 7.02 months of the home care individually, healthcare expenditure decreased significantly. The average OPD healthcare expenditure decreased by 29.01 % in the year 2010 (the BNHI target was 10% reduction), 29.48% in 2011 (the target was 10% reduction), 26.04% in 2012 (the target was 12%), and 26.52% in 2013 (the target was 12%), respectively. Using the reimbursement of service fee to pharmacist as the cost and saving of OPD healthcare expenditure as the benefit, the cost-benefit ration for this thesis study was 1.00 : 3.56. The author’s effort in these few years can helped to save the outpatient healthcare expenses from National Health Insurance program up to NT$938,915 dollars.
In conclusion, under the current pilot project sponsored by the National Health Insurance Administration, inviting pharmacists to conduct home visit and pharmaceutical care is quite feasible and cost beneficial. At patient’s home, pharmacist can collect all the drugs patient is taing, identify drug therapy problems that make the patient’s disease not effective and even has adverse reaction, also, adherence issue can be identified and resolved. By doing so, pharmacist can guarantee to protect the safe and appropriate use of medication and increase patient’s quality of life, and finally help to reduce the waste of healthcare resources.

第一章 緒言 1
第一節 研究背景 1
第二節 研究動機 10
第三節 研究目的 14
第四節 研究假說 15
第二章 文獻探討 17
第一節 居家照護文獻之探討 17
第二節 藥事照護的療效結果測量之文獻探討 28
第三節 國內、外照護研究文獻之探討 43
第三章 研究方法 46
第一節 研究流程 46
第二節 研究分析工具 48
第四章 研究結果 52
第一節 研究結果 52
一、臨床結果 52
二、經濟結果 53
三、人性結果 55
第二節 資料分析結果 58
第五章 討論 82
第六章 結論 93
參考文獻 98
附錄一、高診次藥事居家照護藥師選案辦法 104
附錄二、藥事居家照護報告書 108
附錄三、民眾對藥師所提供居家照護之滿意度調查 109
附錄四、2011 EuroQol Group. EQ-5D-5L 111

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm.
1990;47(3):533-543.
2. Penna RP. Pharmaceutical care: Pharmacys mission for the 1990s. Am J Hosp Pharm. 1990;47:543-549.
3. Wiedenmayer K, Summers RS, Mackie CA, Gous AG, Everard M. In: Developing pharmacy practice- A focus on
patient care. Geneva, Switzerland: WHO Department of Medicine Policy and Standards; 2006
4. 連瑞猛.藥事照護之前瞻願景.藥學雜誌 2011; 26(1): 3-6.
5. 藥師法施行細則.
6. 藥師法. 行政院衛生署法規檢索系統
7. 譚延輝.藥事照護之哲學理念.藥學雜誌 2011;26(1):39-46.
8. 譚延輝.藥事照護執行規範.藥學雜誌 2011; 26(1):33-38.
9. 譚延輝. 藥事照護的病人照顧流程. 藥學雜誌 2011; 26(1): 59-69.
10. 全民健保高診次保險對象藥事居家照護試辦計畫(2010~2013). 中央健康保險局.
11. 全民健保險藥事居家照護試辦計畫期末執行成果報告(2010~2013).中華民國藥師公會全國聯合會.
12. 行政院衛生署(2011). 開源節流降低赤字壓力計畫.中央健康保險局. (2011). 醫療費用總額預算支付制度.from
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=897&WD_ID=897&webdata_id=4025 Accessed December
20.2013.
13. 高危險群的照護計畫. 食品藥物管理局(TFDA). 2012年6月.
14. 行政院衛生署 . (2012). 2012 年承保業務 .
From http://www.doh.gov.tw/CHT2006/DM/DM2_2.
aspx?checkBoard=1&class_no=440. Accessed December 20.2013.
15. 行政院衛生署 . (2012). 國民醫療保健支出個人費用分析 .
from http://www.doh.gov.tw/CHT2006/DM/DM2_p02.
aspx?class_no=440&now_fod_list_ no=12486&level_2&doc_86415. Accessed December 20.2013.
16. 中央健康保險局. (2011). 醫療費用總額預算支付制度. from http://www.nhi.gov.tw/webdata/webdata.aspx?
menu=17&menu_id=897&WD_ID=897&webdata_id=4025. Accessed December 20.2013.
17. 中央健康保險局 (2012). 健保對看病次數過高民眾的關懷輔導
措施.
18. 連瑞猛. 發展台灣藥事照護之過去、現在與未來. 藥學雜誌 2014; 30(1):2-6.
19. ASHP Statement on Pharmaceutical Care. Am J Hosp Pharm 1993; 50:1720-1723.
20. Papers from the Commission to Implement Change in Pharmaceutical Education. Am J Pharm Educ 1993; 57:366-
385.
21. Penna RP. Pharmaceutical care: Pharmacys mission for the 1990s. Am J Hosp Pharm 1990; 47:543-549.
22. Draft statement on pharmaceutical care. Am J Hosp Pharm 1993; 50:126-128.
23. Cipolle RJ, Strand LM, Morley PC. Phamaceutical Care Practice- The Clinician's Guide. 2nd ed. New York:
McGraw-Hill; 2004.
24. Kaplan RM, Anderson JP. The geneal health policy model: An intergrated approach. In: Spilker. B, ed.
Quality of Life Assessments in Clinical Trials. New York: Raven Press; 1990: 131-149.
25. Bennett A, Johnsen S, Smith C, Hurst R, Chen T. A comparative study of two collaborative models for the
provision of domiciliary medication review. Sydney: Faculty of Pharmacy, The Unviersity of Sydney. 2000.
26. Castelino RL, Bajorek BV, Chen TF. Retrospective evaluation of home medicines review by pharmacists in
older Australian patients using the medication appropriateness index. Ann Pharmacother. 2010; 44(12):1922-
1929.
27. Lenaghan E, Holland R, Brooks A. Home-based medication review in a high risk elderly population in primary
care—the POLYMED randomised controlled trial. Age and ageing 2007; 36(3):292-297.
28. 譚延輝. 藥事照護在台灣. 藥學雜誌 2011; 27(3):42-45.
29. 譚延輝. 藥事照護執行規範. 藥學雜誌 2010; 26(1): 33-38.
30. 譚延輝. 藥師執行居家照護之標準作業流程. 藥學雜誌 2011; 26(1): 23-32.
31. 中央健康保險局(2010)全民健保高診次民眾就醫行為改善方案—藥事居家照護試辦計畫. 藥學雜誌 2010; 26(1): 7-12.
32. 中央健康保險局(2012~2013). 「全民健保高診次保險對象藥事居
家照護」試辦計畫.
33. 中華民國藥師公會全國聯合會. 行政院衛生福利部中央健康保險屬(2010~2013).「全民健保險藥事居家照護」試辦計畫.期末執行
成果報告.
34. 中央健康保險局. (2013). 102年度業務執行報告. from
http://www.nhi.gov.tw/webdata/webdata.
aspx?menu=17&menu_id=1023&WD_ID=1043&webdata_id=4351. Accessed January 21.2014.
35. ten Brinke R, Dekker N, et al. Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart
disease and all-cause mortality. Prim Care Diabetes 2008; 2(1): 45-49.
36. Law MR, Wald , NJ et al. By how much and how quickly does reduction in serum cholesterol concentration
lower risk of ischaemic heart disease? BMJ 1994; 308(6925): 367-372.
37. Bernsten, C, Bjorkman I, et al. Improving the well-being of elderly patients via community pharmacy-based
provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18(1):
63-77.
38. Westerlund, T and Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in
drug-related problems. J Clin Pharm The 2009; 34(3): 319-327.
39. Schmader KE, Hanlon JT, et al. Effects of geriatric evaluation and management on adverse drug reactions and
suboptimal prescribing in the frail elderly. Am J Med 2004; 116(6): 394-401.
40. Holland R, Lenaghan E, et al. Does home based medication review keep older people out of hospital? The
HOMER randomised controlled trial." BMJ 2005; 330(7486): 293.
41. Cote I, Farris K, et al. Is adherence to drug treatment correlated with health-related quality of life?
Qual Life Res 2003; 12(6): 621-633.
42. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care pactice. New York: McGraw Hill. 1998.
43. Strand LM. C., Robert J. Morley P C. Pharmaceutical care practice. New York: McGraw-Hill. 2012.
44. 譚延輝.認識藥物治療問題. 藥學雜誌 2011; 26(1): 47-58.
45. Abbey A and Andrews F. Modeling the psychological determinants of life quality. Social Indicators Research
1985; 16(1): 1-34.
46. Patrick DL. Health status and health policy : quality of life in health care evaluation and resource
allocation / Donald L. Patrick, Pennifer Erickson. New York: Oxford University Press. 1993.
47. 姚開屏.健康相關生活品質概念與測量原理之簡介. 臺灣醫學2002; 6(2): 183-192.
48. Wilson IB and Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model
of patient outcomes. JAMA 1995; 273(1): 59-65.
49. Yang G, L Kong, et al. Emergence of chronic non-communicable diseases in China. Lancet 2008;372(9650):
1697-1705.
50. Sun S, Chen J, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic
status, from the National Health Services Survey 2008. Qual Life Res 2011; 20(3): 309-320.
51. Torrance GW. Measurement of health state utilities for economic
appraisal. J Health Econ 1986; 5(1): 1-30.
52. Coons SJ, Rao S, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics
2000; 17(1): 13-35.
53. Ware J E Jr, Gandek B, et al. The equivalence of SF-36 summary health scores estimated using standard and
country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life
Assessment. J Clin Epidemiol 1998; 51(11): 1167-1170.
54. Ware JE Jr, Kosinski M, Gandek B. SF-36 Health Survey: manual
and interpretation guide. Lincoln, RI: QualityMetric Inc, 2000
55. Mahadeva S, Wee HL, et al. The EQ-5D (Euroqol) is avalid generic instrument for measuring quality of life
in patients with dyspepsia. BMC Gastroenterol 2009; 9: 20.
56. Glasziou PP, Clarke P, et al. Cost-effectiveness of lowering blood pressure with a fixed combination of
perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. Med J Aust 2010;
193(6): 320-324.
57. Bladh L, Ottosson E, et al. Effects of a clinical pharmacist service on health-related quality of life and
prescribing of drugs: a randomised controlled trial. BMJ Qual Saf 2011; 20(9): 738-746.
58.Rabin R and de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33(5):337-
343
59. Badia X, Schiaffino A, et al. Using the EuroQoI 5-D in the Catalan general population: feasibility and
construct validity. Qual Life Res 1998; 7(4): 311-322.
60. Myers C and Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual
Life Res 1999; 8(1-2): 9-16.
61. Herdman M, Gudex C, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-
5D-5L). Qual Life Res 2011; 20(10): 1727-1736.
62. Risser NL. Development of an Instrument to Measure Patient Satisfaction with Nurses and Nursing Care in
Primary Care Settings. Nursing Research 1975; 24(1).
63. Wiedenmayer K. Developing Pharmacy Practice: A Focus on Patient Care : Handbook, World Health Organization.
2006.
64.蔡輝彥. 建立住院病患之中藥藥事照護模式計畫. 中醫藥年報2010; 29(2)
65. Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of healthcare
programmes, 2nd ed. Oxford: Oxford University Press. 1997.
66. 譚延輝. 台灣藥事居家照護之執行與成效. 中國執業藥師
2012;9(11):13-16
67. 陳淑梅, 李季黛, 陳妙婷, 李建立, 曾碧萊. 醫院藥師於養護機構建置用藥安全機制之探討. 長期照護雜誌2011;15 (3): 259-272
68. 譚延輝. 高診次民眾藥事居家照護之成效. 長期照護雜誌 2012; 16(2): 135-142
69. Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki RT. Pharmacist intervention for glycaemic control in the
community(the RxING study). BMJ Open 2013;3:e003154..
70. Magid DJ, Olson KL, Billups SJ, et al. A pharmacist-led, American Heart Association Heart360 Web-enabled
home blood pressure monitoring program. Circ Cardiovasc Qual Outcomes 2013; 6(2):157-163.
71. Flanagan P, Kainth S, Nissen L. Satisfaction survey for a medication management program: satisfaction
guaranteed? Can J Hosp Pharm 2013; 66(6):355-360.
72. Alghurair SA, Simpson SH, Guirguis LM. What elements of the patient-pharmacist relationship are associated
with patient satisfaction? Patient Prefer Adherence 2012; 6:663-676.
73. Al-Arifi MN. Patients’ perception, views and satisfaction with
pharmacists’ role as health care provider in community pharmacy setting at Riyadh, Saudi Arabia. Saudi
Pharm J 2012; 20(4): 323-330.